Treatment of iron overload in thalassemia

Pediatric Endocrinology Reviews

Volumn 6, Issue SUPPL. 1, 2008, Pages 208-213

  Cianciulli, Paolo ^a  

^a S EUGENIO HOSPITAL   (Italy)

Author keywords

Anemia, iron overload; Deferasirox; Deferiprone; Desfernoxamine; Iron chelation therapy; Thalassemia

Indexed keywords

CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON CHELATING AGENT;

AGRANULOCYTOSIS; BLOOD TRANSFUSION; CARDIOMYOPATHY; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HEMOSIDEROSIS; HUMAN; IRON OVERLOAD; LIFE EXPECTANCY; MONOTHERAPY; MORTALITY; NEUTROPENIA; NONHUMAN; NORMAL VALUE; PATIENT COMPLIANCE; PATIENT MONITORING; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THALASSEMIA MAJOR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PATIENT COMPLIANCE; THALASSEMIA;

EID: 58149479414     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Guidelines for the clinical management of thalassaemia. 2007 (cited 2008 June 8); 2nd Edition: (Available from: http://www.thalassaemia.org.cy/ MyData/Books/Guidelines%20to%20the%20Clinical%20Management%20of%20 Thalassaemia.PDF
2. Yang PHL, Keam SJ, Keating GM. Deferasirox. Drugs 2007;67:2211-2230
3. Barton JC. Optimal management strategies for chronic iron overload. Drugs 2007;67:685-700
4. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-252
5. Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med 1985;106:147-153
6. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193
7. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;1;331:567-573
8. Hershko C, Link G, Konijn AM, Cabantchik ZI. Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci 2005;1054:124-135
9. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;1;102:2670-2677
10. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Otivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;1;107:3455-3462
11. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008;5;111:583-587
12. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998;30;850:227-231
13. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985;20;312:1600-1603
14. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990;84:113-117
15. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000;15;95:1229-1236
16. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36
17. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;10;355:2051-2052
18. Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta-thalassemia major and other transfusion-dependent diseases. Drugs 1999;58:553-578
19. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;1;102:17-24
20. Cohen AR, Galanelto R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000;08:305-312
21. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;1;102:1583-1587
22. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330-336
23. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;17;360:516-520
24. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;1;107:3738-3744
25. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-364
26. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica 2003;88:1423-1425
27. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;10;115:1876-1884
28. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005;74:84-85
29. Porcu M, Landis N, Salis S, Corda M, Orru P, Serra E, Usai B, Matta G, Galanello R. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. Eur J Heart Fail 2007;9:320-322
30. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006;134:438-444
31. Novartis Pharmaceuticals. Deferasirox (Exjade®): Summary of product characteristics. 2008 (cited 2008 9 Jun); Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/exjade/H-670-Pl-en.pdf
32. Steinhauser S, Heinz U, Bartoloma M, Weyhermüller T, Hanspeter N, Hegetschweiler K. Complex formation of ICL670 and related ligands with FeIII and FeII. Eur J Inorg Chem 2004;21:4177-4192
33. FDA approves first oral drug for chronic iron overload. 2005 (cited 2007 April 1); Available from: http://www.fda.gov/bbs/topics/news/2005/ NEW01258.html
34. Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, Alberti D. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003;10:1065-1076
35. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;10;361:1597-602
36. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daity, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873-880
37. Cappellini MD, Vichinsky E, Galanello R, Piga A, Williamson P, Porter JB. Long-Term Treatment with Deferasirox (Exjade®, ICL670), a Once-Daily Oral Iron Chelator, Is Effective in Patients with Transfusion-Dependent Anemias. ASH Annual Meeting Abstracts. Blood 2007;110:2777
38. Piga A, Vichinsky E, Forni GL, Kilinc Y, Maseruka H, Kattamis A. Long-Term Efficacy and Safety with Deferasirox (Exjade®, ICL670), a Once-Daily Oral Iron Chelator, in Pediatric Patients. ASH Annual Meeting Abstracts. Blood 2007;110:2774
39. Porter JB, Cohen AR, Ford JM, Cappellini MD. Impact of Dose Adjustments on Serum Ferritin (SF) Levels during Long-Term Treatment with Once-Daily, Oral Deferasirox (Exjade®, ICL670). ASH Annual Meeting Abstracts. Blood 2007;110:2778
40. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005;1;106:3242-3250
41. Wood JC, Otto-Duessel M, Gonzalez I, Aguilar MI, Shimada H, Nick H, Nelson M, Moats R. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 2006;148:272-280
42. Eleftheriou P, Tanner M, Pennell D, Porter J. Response of myocardial T2 to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis (abstract). Haematologica 2006;91(Suppl 1):999
43. Wood J, Thompson AA, Paley C, Kang B, Giardina P, Harmatz P, Virkus J, Coates T. Exjade® Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2 Study. ASH Annual Meeting Abstracts. Blood 2007;110:2781
44. Daar S, Taher A, Pathare A, Nick H, Krahn U and Hadler D. Sustained Protection from Labile Plasma Iron (LPI) with the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670) in Iron-Overloaded β-Thalassemia Patients. ASH Annual Meeting Abstracts. Blood 2006;108:1773
45. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008;83:398-402